Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma
Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma
复制标题
DOI：
10.1038/sj.bmt.1705649
复制
发表时间：
2007-05-01
影响因子：
4.8
通讯作者：
Nagafuji, K.
中科院分区：
文献类型：
--
作者：
Kamezaki, K.;Kikushige, Y.;Nagafuji, K.
为了研究自体移植前给予利妥昔单抗对外周血干细胞（PBSC）动员和植入的影响，我们回顾性分析了43例初诊弥漫性大B细胞淋巴瘤患者的结局，这些患者在自体PBSC移植（PBSCT）前接受CHOP化疗联合或不联合利妥昔单抗作为一线治疗。在非利妥昔单抗组和利妥昔单抗组之间，外周血干细胞中CD 34（+）细胞的数量没有差异。虽然利妥昔单抗组的B细胞完全从PBSC中去除，但我们发现PBSC上CXCR-4、VLA-4和c-Kit的表达没有差异，表明利妥昔单抗不影响这些粘附分子的表达，这可能参与了动员机制。两组中性粒细胞和血小板的恢复、移植相关毒性和移植后并发症无显著差异。尽管随访时间较短，但两组之间的无进展生存率无显著差异。这些结果表明利妥昔单抗对PBSC的动员和植入没有不利影响。需要更大规模的研究来确定利妥昔单抗对PBSC动员和功能的影响，以及接受利妥昔单抗自体PBSCT的患者是否存在生存优势。
To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34(+) cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab.